New Drug Indication Approval - Sep 2019
Product Name
|
CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG
|
Active Ingredient
|
Cabozantinib
|
Product Registrant
|
IPSEN PHARMA PTE LTD |
Date of Approval
|
06/09/2019 |
Indications:
Renal Cell Carcinoma (RCC)
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk (see section 5.1).
Hepatocellular Carcinoma (HCC)
CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
|
Product Name
|
XARELTO FILM COATED TABLETS 2.5MG
|
Active Ingredient
|
Rivaroxaban |
Product Registrant
|
BAYER (SOUTH EAST ASIA) PTE LTD |
Date of Approval
|
26/09/2019 |
Indications: XARELTO, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in adult patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) at high risk of ischemic events. |
Product Name
|
BOOSTRIX VACCINE
|
Active Ingredient
|
Diphtheria toxoid, Tetanus toxoid, Bordetella pertussis antigens |
Product Registrant
|
GLAXOSMITHKLINE PTE LTD |
Date of Approval
|
27/09/2019 |
Indications: Boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards.
|
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals